Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...
The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
The U.S. stock market was down for the week despite a positive Friday, as tariff developments from the Trump administration ...
A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...
Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results